Oncology

The FDA approves a once-monthly dosing schedule for amivantamab and hyaluronidase-lpuj to optimize administration and cut down infusion times.

The biosimilar is a cost-effective treatment for patients with conditions caused by cancer treatment.

Explore the balance of ambition and self-care in cancer care, emphasizing curiosity, collaboration, and the importance of sustainable productivity.

Amivantamab with lazertinib emerges as a promising frontline therapy for EGFR-mutated metastatic NSCLC, enhancing overall survival and treatment tolerability.

Registry data show COVID-era care disruptions cut 1-year cancer survival, adding 17,390 excess deaths—the biggest losses in late-stage and older patients.

Study links GLP-1 receptor agonists plus progestin to lower endometrial cancer risk, hinting at new prevention and treatment paths with fewer hysterectomies.

MammaPrint genomic profiling guides personalized HR-positive breast cancer treatment, helping pharmacists and oncology teams reduce chemotherapy use while protecting outcomes.

Patients need evidence that reflects real benefit.

Explore emerging evidence on aspirin’s potential role in reducing cancer risk and improving survival.

NCCN-backed MammaPrint stratifies HR+ breast cancer, pinpointing who needs anthracyclines and how pharmacists help personalize oncology care.

GDF15 can reshape prostate cancer prognosis and treatment; pharmacists track emerging biomarker panels and targeted therapies for metastatic disease.

H. pylori requires diagnosis, antibiotic- and acid-suppression-based therapy, and post-treatment eradication confirmation to prevent gastritis and cancer.

The phase 3 ADRIATIC trial demonstrates that consolidation durvalumab following concurrent chemoradiotherapy improves survival while maintaining health-related quality of life.

Oncology pharmacists use MammaPrint to target anthracyclines in high-risk breast cancer, sparing others cardiotoxicity and severe nausea.

FDA approval expands pembrolizumab (Keytruda) for PD‑L1+ platinum‑resistant ovarian cancer, pairing with paclitaxel ± bevacizumab to improve survival outcomes.

RESTORE trial data show investigational elritercept improves myelofibrosis anemia and cytopenias, reduces transfusions, and guides pharmacists on monitoring with ruxolitinib.

DPYD Testing reshapes oncology dosing for 5‑FU/capecitabine to prevent toxicity and personalize chemotherapy.

NCCN updates can guide pharmacists to tailor chemotherapy for HR+/HER2- breast cancer using MammaPrint and FLEX survival data.

Explore how pharmacists can support patients with pancreatic cancer taking atebimetinib as Immuneering leaders and oncologists discuss tolerability, education, and survival-focused phase 3 trial goals.

Emerging ultraprecision therapies target CALR mutations in myelofibrosis, promising more effective treatments and improved patient outcomes for pharmacists.

Study results suggest young participants who survived cancer have difficulty in areas such as memory, attention, and ability to process information compared with those who did not have cancer.

Experts discuss how atebimetinib and adjusted chemotherapy schedules enhance tolerability and treatment duration for patients with pancreatic cancer.

Phase 1 data show oral NSD2 inhibitor KTX-1001 delivers durable disease control in high-risk myeloma, with manageable thrombocytopenia and combo plans.

Experts discuss the role of pharmacists in CAR T-cell and gene therapy at the 2026 ASTCT Tandem Meeting in Salt Lake City.

Dato-DXd is a promising first-line treatment for metastatic triple-negative breast cancer, enhancing patient outcomes.

KTX-1001, a novel oral inhibitor of NSD2, demonstrates early clinical activity and manageable safety in heavily pretreated multiple myeloma.

Experts discuss groundbreaking data on pancreatic cancer treatment, revealing a 64% survival rate and its potential to transform patient care and outcomes.